Eli Lilly leveraging machine learning to find coronavirus treatment

Amy Baxter | | Health Exec | Precision Medicine

Pharmaceutical giant Eli Lilly has partnered with AbCellera Biologics, a biotechnology company based in Canada, to address the new coronavirus crisis by developing antibody products to treat and prevent the virus, The Wall Street Journal reported.

AbCellera uses machine learning to find antibody therapies and received a blood sample in February from a patient diagnosed with COVID-19. By screening more than 5 million immune cells and using machine learning to identify which can produce antibodies to neutralize COVID-19, AbCellera identified more than 500 promising antibodies in less than one week.

AbCellera is just one of many companies in the space leveraging AI and machine learning to deal with the pandemic and find desperately-needed solutions.

See the full story below:

Biotech Company Uses Machine Learning to Find Coronavirus Therapies

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.